DE69729283T2
(en)
*
|
1996-03-20 |
2005-05-25 |
Immunomedics, Inc. |
GLYCOSYLATED IgG ANTIBODIES
|
US6953675B2
(en)
*
|
1997-11-06 |
2005-10-11 |
Immunomedics, Inc. |
Landscaped antibodies and antibody fragments for clinical use
|
US6962702B2
(en)
|
1998-06-22 |
2005-11-08 |
Immunomedics Inc. |
Production and use of novel peptide-based agents for use with bi-specific antibodies
|
US7829064B2
(en)
|
1999-05-10 |
2010-11-09 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods
|
US8119101B2
(en)
|
1999-05-10 |
2012-02-21 |
The Ohio State University |
Anti-CD74 immunoconjugates and methods of use
|
US8383081B2
(en)
|
1999-05-10 |
2013-02-26 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods of use
|
WO2001061351A1
(en)
*
|
2000-02-17 |
2001-08-23 |
Laboratory Of Molecular Biophotonics |
Method for quantitatively detecting antigen
|
US7321026B2
(en)
*
|
2001-06-27 |
2008-01-22 |
Skytech Technology Limited |
Framework-patched immunoglobulins
|
EP1448780A4
(en)
*
|
2001-10-15 |
2005-08-31 |
Immunomedics Inc |
Direct targeting binding proteins
|
KR101027889B1
(en)
*
|
2001-10-15 |
2011-04-07 |
아이비씨 파마슈티컬스, 인코퍼레이티드 |
Affinity enhancement agents
|
AU2002359568B2
(en)
*
|
2001-12-03 |
2008-02-21 |
Alexion Pharmaceuticals, Inc. |
Hybrid antibodies
|
US7393648B2
(en)
*
|
2001-12-03 |
2008-07-01 |
Alexion Pharmaceuticals, Inc. |
Hybrid antibodies
|
AU2002364531A1
(en)
*
|
2001-12-26 |
2003-07-24 |
Ibc Pharmaceuticals |
Methods of generating multispecific, multivalent agents from vh and vl domains
|
KR101033196B1
(en)
|
2002-02-14 |
2011-05-09 |
이뮤노메딕스, 인코오포레이티드 |
Anti-CD20 antibodies and fusion proteins thereof and methods of use
|
US8287864B2
(en)
*
|
2002-02-14 |
2012-10-16 |
Immunomedics, Inc. |
Structural variants of antibodies for improved therapeutic characteristics
|
AU2003224624B2
(en)
|
2002-02-21 |
2008-08-28 |
Duke University |
Reagents and treatment methods for autoimmune diseases
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US7662925B2
(en)
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
KR101017732B1
(en)
|
2002-03-01 |
2011-02-28 |
이뮤노메딕스, 인코오포레이티드 |
Internalizing anti-CD74 antibodies and methods of use
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
HUE054986T2
(en)
|
2002-03-01 |
2021-10-28 |
Immunomedics Inc |
Immunoconjugate comprising humanised rs7 antibodies
|
KR101143035B1
(en)
|
2002-06-14 |
2012-05-08 |
이뮤노메딕스, 인코오포레이티드 |
Monoclonal antibody hPAM4
|
WO2004013180A2
(en)
*
|
2002-08-01 |
2004-02-12 |
Immunomedics, Inc. |
Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
|
US7541440B2
(en)
|
2002-09-30 |
2009-06-02 |
Immunomedics, Inc. |
Chimeric, human and humanized anti-granulocyte antibodies and methods of use
|
EP2311870A1
(en)
*
|
2002-11-26 |
2011-04-20 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
US8420086B2
(en)
|
2002-12-13 |
2013-04-16 |
Immunomedics, Inc. |
Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
|
US7534427B2
(en)
*
|
2002-12-31 |
2009-05-19 |
Immunomedics, Inc. |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
EP2216342B1
(en)
|
2003-07-31 |
2015-04-22 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US8883160B2
(en)
*
|
2004-02-13 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
US9550838B2
(en)
|
2004-02-13 |
2017-01-24 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
US7276585B2
(en)
|
2004-03-24 |
2007-10-02 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US9200079B2
(en)
|
2004-11-12 |
2015-12-01 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
AU2006218454B2
(en)
|
2005-03-03 |
2011-11-17 |
Immunomedics, Inc. |
Humanized L243 antibodies
|
WO2006106903A1
(en)
|
2005-03-31 |
2006-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
sc(Fv)2 STRUCTURAL ISOMERS
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
KR101360671B1
(en)
|
2005-06-10 |
2014-02-07 |
추가이 세이야쿠 가부시키가이샤 |
Pharmaceutical compositions containing sc(Fv)2
|
KR101367544B1
(en)
|
2005-06-10 |
2014-02-26 |
추가이 세이야쿠 가부시키가이샤 |
Stabilizer for protein preparation comprising meglumine and use thereof
|
KR20080025174A
(en)
|
2005-06-23 |
2008-03-19 |
메디뮨 인코포레이티드 |
Antibody formulations having optimized aggregation and fragmentation profiles
|
JP2009502972A
(en)
*
|
2005-07-29 |
2009-01-29 |
アムジエン・インコーポレーテツド |
Formulation that suppresses protein aggregation
|
CA2624189A1
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
CA2625998C
(en)
|
2005-10-06 |
2015-12-01 |
Xencor, Inc. |
Optimized anti-cd30 antibodies
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
WO2007061936A2
(en)
*
|
2005-11-18 |
2007-05-31 |
New England Medical Center Hospitals, Inc. |
Clearance of abnormal iga1 in iga1 deposition diseases
|
EP2650306A1
(en)
|
2006-03-06 |
2013-10-16 |
Aeres Biomedical Limited |
Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
EP1998799B8
(en)
|
2006-03-06 |
2014-03-05 |
Medlmmune, LLC |
Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
WO2008022152A2
(en)
|
2006-08-14 |
2008-02-21 |
Xencor, Inc. |
Optimized antibodies that target cd19
|
AU2007299843B2
(en)
|
2006-09-18 |
2012-03-08 |
Xencor, Inc |
Optimized antibodies that target HM1.24
|
AU2008211227B2
(en)
|
2007-01-30 |
2014-04-17 |
Epivax, Inc. |
Regulatory T cell epitopes, compositions and uses thereof
|
EP4098661A1
(en)
|
2007-12-26 |
2022-12-07 |
Xencor, Inc. |
Fc variants with altered binding to fcrn
|
CN102159243B
(en)
*
|
2008-07-21 |
2015-08-19 |
免疫医疗公司 |
For the structural variant of the antibody for the treatment of feature improved
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
PL2396036T3
(en)
|
2009-02-13 |
2017-12-29 |
Immunomedics, Inc. |
Immunoconjugates with an intracellularly-cleavable linkage
|
WO2010096394A2
(en)
|
2009-02-17 |
2010-08-26 |
Redwood Biosciences, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
WO2010123885A2
(en)
|
2009-04-20 |
2010-10-28 |
Tufts Medical Center, Inc. |
Iga1 protease polypeptide agents and uses thereof
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
JP5996429B2
(en)
*
|
2009-09-03 |
2016-09-21 |
ジェネンテック, インコーポレイテッド |
Method for treatment, diagnosis and monitoring of rheumatoid arthritis
|
EP3009455A1
(en)
|
2009-09-16 |
2016-04-20 |
Immunomedics Inc. |
Class i anti-cea antibodies and uses thereof
|
WO2011068845A1
(en)
|
2009-12-02 |
2011-06-09 |
Immunomedics, Inc. |
Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
|
EP2523680A4
(en)
*
|
2010-01-11 |
2013-06-19 |
Ct Molecular Med & Immunology |
Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
|
US8362210B2
(en)
|
2010-01-19 |
2013-01-29 |
Xencor, Inc. |
Antibody variants with enhanced complement activity
|
CA2824143C
(en)
|
2011-01-14 |
2018-12-18 |
Redwood Bioscience, Inc. |
Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
|
KR20140022815A
(en)
|
2011-02-28 |
2014-02-25 |
제넨테크, 인크. |
Biological markers and methods for predicting response to b-cell antagonists
|
JP6024025B2
(en)
|
2011-05-02 |
2016-11-09 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
Ultrafiltration concentration of allotype-selected antibodies for small volume administration
|
JP6271251B2
(en)
*
|
2011-10-05 |
2018-01-31 |
中外製薬株式会社 |
An antigen-binding molecule that promotes elimination of an antigen containing a sugar chain receptor-binding domain from plasma
|
US9757458B2
(en)
|
2011-12-05 |
2017-09-12 |
Immunomedics, Inc. |
Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
|
WO2013085893A1
(en)
|
2011-12-05 |
2013-06-13 |
Immunomedics, Inc. |
Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
|
AU2013290424B2
(en)
|
2012-07-19 |
2018-01-25 |
Redwood Bioscience, Inc. |
Antibody specific for CD22 and methods of use thereof
|
WO2014028560A2
(en)
|
2012-08-14 |
2014-02-20 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
EP2900277B1
(en)
|
2012-12-13 |
2022-02-16 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
ES2819573T3
(en)
|
2012-12-13 |
2021-04-16 |
Immunomedics Inc |
Method for Producing Antibody-SN-38 Immunoconjugates with a CL2A Linker
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
IL275376B2
(en)
*
|
2013-03-11 |
2024-01-01 |
Genzyme Corp |
Hyperglycosylated binding polypeptides
|
US20160106860A1
(en)
|
2013-05-02 |
2016-04-21 |
Glykos Finland Oy |
Conjugates of a glycoprotein or a glycan with a toxic payload
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
CA2922478C
(en)
|
2013-08-26 |
2020-09-29 |
MabVax Therapeutics, Inc. |
Nucleic acids encoding human antibodies to sialyl-lewisa
|
US20160257764A1
(en)
|
2013-10-14 |
2016-09-08 |
Synaffix B.V. |
Glycoengineered antibody, antibody-conjugate and methods for their preparation
|
EP3057618B1
(en)
|
2013-10-14 |
2022-12-14 |
SynAffix B.V. |
Glycoengineered antibody, antibody-conjugate and methods for their preparation
|
US9987373B2
(en)
|
2013-10-14 |
2018-06-05 |
Synaffix B.V. |
Modified glycoprotein, protein-conjugate and process for the preparation thereof
|
CA2937236C
(en)
|
2014-02-21 |
2023-03-07 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to trop-2 expressing cells
|
CN106029098A
(en)
|
2014-02-25 |
2016-10-12 |
免疫医疗公司 |
Humanized RFB4 anti-CD22 antibody
|
NZ764877A
(en)
|
2014-06-04 |
2023-12-22 |
Biontech Res And Development Inc |
Human monoclonal antibodies to ganglioside gd2
|
CA2953567C
(en)
|
2014-06-24 |
2023-09-05 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
WO2015197919A1
(en)
|
2014-06-25 |
2015-12-30 |
Glykos Finland Oy |
Antibody drug conjugates binding to high-mannose n-glycan
|
US10973920B2
(en)
|
2014-06-30 |
2021-04-13 |
Glykos Finland Oy |
Saccharide derivative of a toxic payload and antibody conjugates thereof
|
JP6678941B2
(en)
|
2014-10-07 |
2020-04-15 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
Use of neoadjuvant antibody-drug conjugates
|
JP6746845B2
(en)
|
2015-04-22 |
2020-08-26 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating TROP-2 positive cancer cells
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
PL3313443T3
(en)
|
2015-06-25 |
2023-11-06 |
Immunomedics, Inc. |
Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
SI3316885T1
(en)
|
2015-07-01 |
2021-09-30 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
CN108601841A
(en)
|
2016-02-10 |
2018-09-28 |
免疫医疗公司 |
The combination of ABCG2 inhibitor and SACITUZUMAB GOVITECAN (IMMU-132) overcome the resistance to SN-38 in the cancer for expressing TROP-2
|
JP2019515677A
(en)
|
2016-04-26 |
2019-06-13 |
アール.ピー.シェーラー テクノロジーズ エルエルシー |
Antibody conjugates and methods of making and using the same
|
CA3016917A1
(en)
|
2016-04-27 |
2017-11-02 |
Immunomedics, Inc. |
Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
|
EP3468587A4
(en)
|
2016-06-09 |
2020-02-19 |
University of Leicester |
Monoclonal antibodies, compositions and methods for detecting mucin -like protein (mlp) as a biomarker for ovarian and pancreatic cancer
|
CN110248668B
(en)
|
2016-12-15 |
2023-05-30 |
杜克大学 |
Antibodies and methods for depleting regulatory B10 cells and combination with immune checkpoint inhibitors
|
EP3600283A4
(en)
|
2017-03-27 |
2020-12-16 |
Immunomedics, Inc. |
Treatment of trop-2 expressing triple negative breast cancer with sacituzumab govitecan and a rad51 inhibitor
|
CA3044082A1
(en)
|
2017-04-03 |
2018-10-11 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
WO2019073069A1
(en)
|
2017-10-13 |
2019-04-18 |
Boehringer Ingelheim International Gmbh |
Human antibodies to thomsen-nouvelle (tn) antigen
|
EP3707167A4
(en)
*
|
2017-11-09 |
2021-08-04 |
National Research Council of Canada |
Antibody glycoconjugates and methods of production and use
|
IT202100003599A1
(en)
|
2021-02-17 |
2022-08-17 |
Inderst Srl |
PROTECTIVE DEVICE FOR ESPALLER CULTIVATION
|
JPWO2022239720A1
(en)
|
2021-05-10 |
2022-11-17 |
|
|